Association Between Oral Hypofunction, Sarcopenia and Social Frailty in Community-dwelling Older … (NCT07658625) | Clinical Trial Compass
CompletedNot Applicable
Association Between Oral Hypofunction, Sarcopenia and Social Frailty in Community-dwelling Older Adults
Taiwan200 participantsStarted 2025-11-14
Plain-language summary
Previous studies have provided a preliminary understanding of the likelihood of sarcopenia and the prevalence of sarcopenia in the elderly in the community. due to the interaction between physiological and social factors, this study aims to conduct a correlation study on muscle mass, oral function and social frailty in the elderly living in the community.
This study，the Makizako social frailty screening index questionnaire and the Tilburg Frailty Indicator will be used to assess the social frailty status of the study participants. Correlation analysis with sarcopenia and oral dysfunction was also conducted to better understand the interaction between nutrition, physiology, and social connection in the elderly, which will be helpful for formulating relevant policies and promoting healthy aging in the future in extremely elderly countries.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Group A-Inclusion Criteria:
* 65 years old or above
* general public or institutionalized for 3 months or more
* those who accept the experimental design and are willing to sign the consent form
* dietary sources are oral intake
* those who are diagnosed as having possible sarcopenia by researchers
Group B-Inclusion Criteria:
* 65 years old or above
* general public or institutionalized for 3 months or more
* those who accept the experimental design and are willing to sign the consent form
* dietary sources are oral intake
* those who were determined by researchers to be non-probable sarcopenia
Group A、B-Exclusion Criteria:
* comorbidities, critical illness, pre- and post-major surgery, cancer, renal failure, liver failure, kidney disease, liver disease, malignant tumors within the past five years, inflammatory conditions (c-reactive protein \>10mg/dL)
* severely malnourished people
* long-term force-feeding
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Based on the results of empirical research on sarcopenia in Asian countries, a diagnostic consensus was established.
Timeframe: Baseline
Trial details
NCT IDNCT07658625
SponsorChang Gung University of Science and Technology